Fertility and Sterility
Volume 91, Issue 3 , Pages 842-850 , March 2009

A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome

  • Dorte Glintborg, M.D., Ph.D.

      Affiliations

    • Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark
    • Corresponding Author InformationReprint requests: Dorte Glintborg, Odense University Hospital, Kløvervænget 6, Third floor, DK-5000 Odense, Denmark.
    • ,
  • Anne Pernille Hermann, M.D., Ph.D.

      Affiliations

    • Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark
    • ,
  • Claus Hagen, M.D., Dr.Sci.

      Affiliations

    • Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark
    • ,
  • Lars Thorbjørn Jensen, M.D.

      Affiliations

    • Department of Clinical Physiology, Glostrup Hospital, Glostrup, Denmark
    • ,
  • Jan Frystyk, M.D., Ph.D., Dr.Sci.

      Affiliations

    • Medical Research Laboratories, Clinical Institute and Medical Department M (Diabetes and Endocrinology), Aarhus University Hospital, Aarhus, Denmark
    • ,
  • Paul Bennett, Ph.D.

      Affiliations

    • Statens Serum Institute, Copenhagen, Denmark
    • ,
  • Allan Flyvbjerg, M.D., Dr.Sci.

      Affiliations

    • Medical Research Laboratories, Clinical Institute and Medical Department M (Diabetes and Endocrinology), Aarhus University Hospital, Aarhus, Denmark
    • ,
  • Marianne Andersen, M.D., Ph.D.

      Affiliations

    • Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark

Received 21 October 2007 ,Revised 31 December 2007 ,Accepted 31 December 2007.

References 

  1. Glintborg D, Hermann AP, Brusgaard K, Hangaard J, Hagen C, Andersen M. Significantly higher adrenocorticotropin-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls. J Clin Endocrinol Metab. 2005;90:1347–1353
  2. Azziz R, Black V, Hines GA, Fox LM, Boots LR. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab. 1998;83:2317–2323
  3. Kelestimur F, Sahin Y. Alternate pathway 17,20-lyase enzyme activity in the adrenals is enhanced in patients with polycystic ovary syndrome. Fertil Steril. 1999;71:1075–1078
  4. Bjorntorp P. Body fat distribution, insulin resistance, and metabolic diseases. Nutrition. 1997;13:795–803
  5. Stewart PM, Shackleton CH, Beastall GH, Edwards CR. 5 Alpha-reductase activity in polycystic ovary syndrome. Lancet. 1990;335:431–433
  6. Rodin A, Thakkar H, Taylor N, Clayton R. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase. N Engl J Med. 1994;330:460–465
  7. Chin D, Shackleton C, Prasad VK, Kohn B, David R, Imperato-McGinley J, et al. Increased 5alpha-reductase and normal 11beta-hydroxysteroid dehydrogenase metabolism of C19 and C21 steroids in a young population with polycystic ovarian syndrome. J Pediatr Endocrinol Metab. 2000;13:253–259
  8. Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W. Beyond adrenal and ovarian androgen generation: increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2760–2766
  9. Draper N, Stewart PM. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol. 2005;186:251–271
  10. Tomlinson JW, Stewart PM. Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase. Best Pract Res Clin Endocrinol Metab. 2001;15:61–78
  11. Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:737–754
  12. Skalba P, Dabkowska-Huc A, Kazimierczak W, Samojedny A, Samojedny MP, Chelmicki Z. Content of 5-alpha-reductase (type 1 and type 2) mRNA in dermal papillae from the lower abdominal region in women with hirsutism. Clin Exp Dermatol. 2006;31:564–570
  13. Serafini P, Lobo RA. Increased 5 alpha-reductase activity in idiopathic hirsutism. Fertil Steril. 1985;43:74–78
  14. Tsilchorozidou T, Honour JW, Conway GS. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates. J Clin Endocrinol Metab. 2003;88:5907–5913
  15. Jakimiuk AJ, Weitsman SR, Magoffin DA. 5alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1999;84:2414–2418
  16. Glintborg D, Henriksen JE, Andersen M, Hagen C, Hangaard J, Rasmussen P, et al. The prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 caucasian, premenopausal women with hirsutism as primary diagnosis. Fertil Steril. 2004;82:1570–1579
  17. Franks S. Growth hormone and ovarian function. Baillieres Clin Endocrinol Metab. 1998;12:331–340
  18. Homburg R. Growth hormone and fertility—clinical studies. Horm Res. 1996;45:81–85
  19. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev. 2003;CD003053
  20. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327:951–953
  21. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 2002;51:797–802
  22. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784–2791
  23. Glintborg D, Stoving RK, Hagen C, Hermann AP, Frystyk J, Veldhuis JD, et al. Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:5605–5612
  24. Livingstone DE, Kenyon CJ, Walker BR. Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats. J Endocrinol. 2000;167:533–539
  25. Glintborg D, Hermann AP, Andersen M, Hagen C, Beck-Nielsen H, Veldhuis JD, et al. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertil Steril. 2006;86:385–397
  26. Lykkesfeldt G, Bennett P, Lykkesfeldt AE, Micic S, Moller S, Svenstrup B. Abnormal androgen and oestrogen metabolism in men with steroid sulphatase deficiency and recessive X-linked ichthyosis. Clin Endocrinol (Oxf). 1985;23:385–393
  27. Frystyk J, Dinesen B, Orskov H. Noncompetitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul. 1995;5:169–176
  28. Frystyk J, Tarnow L, Krarup HT, Parving HH, Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia. 2005;48:1911–1918
  29. Nielsen MD, Lund JO, Munck O. Urinary excretion of tetrahydroaldosterone in normal subjects and in patients with adrenal insufficiency and Conn's syndrome. Acta Endocrinol (Copenh). 1972;71:498–511
  30. Nielsen MD, Binder C, Starup J. Urinary excretion of different corticosteroid-metabolites in oral contraception and pregnancy. Acta Endocrinol (Copenh). 1969;60:473–485
  31. Palermo M, Shackleton CH, Mantero F, Stewart PM. Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf). 1996;45:605–611
  32. Shackleton CH. Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research. J Steroid Biochem Mol Biol. 1993;45:127–140
  33. Pincus SM. Approximate entropy as a measure of system complexity. Proc Natl Acad Sci U S A. 1991;88:2297–2301
  34. Altman DG. Practical statistics for medical research. London, UK: Chapman & Hall/CRC; 1991;199–202
  35. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest. 1995;96:801–810
  36. Zhang LH, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci U S A. 1995;92:10619–10623
  37. Romualdi D, Giuliani M, Draisci G, Costantini B, Cristello F, Lanzone A, et al. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. Fertil Steril. 2007;88:131–138
  38. Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod. 2003;18:1210–1218
  39. Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:3835–3840
  40. Guido M, Romualdi D, Suriano R, Giuliani M, Costantini B, Apa R, et al. Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Hum Reprod. 2004;19:534–539
  41. Charbonneau A, The VL. Genomic organization of a human 5beta-reductase and its pseudogene and substrate selectivity of the expressed enzyme. Biochim Biophys Acta. 2001;1517:228–235
  42. Walker BR, Rodin A, Taylor NF, Clayton RN. Endogenous inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 do not explain abnormal cortisol metabolism in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2000;52:77–80
  43. Berger J, Tanen M, Elbrecht A, Hermanowski-Vosatka A, Moller DE, Wright SD, et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem. 2001;276:12629–12635
  44. Glintborg D, Hermann A, Brusgaard K, Hangaard J, Hagen C, Andersen M. Significantly higher ACTH-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared to healthy controls. J Clin Endocrinol Metab. 2005;90:1347–1353
  45. Vrbikova J, Bicikova M, Tallova J, Hill M, Starka L. Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2002;110:74–76
  46. Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol. 2003;17:51–56
  47. Unluhizarci K, Kelestimur F, Bayram F. Insulin-sensitizing agents and their effect on adrenal androgens. Fertil Steril. 2000;74:1058–1059
  48. Mitkov M, Pehlivanov B, Terzieva D. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2006;126:93–98
  49. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab. 2002;87:1555–1559
  50. La Marca A, Morgante G, Paglia T, Ciotta L, Cianci A, De Leo V. Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. Fertil Steril. 1999;72:985–989
  51. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86:1626–1632
  52. Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod. 2003;18:1618–1625
  53. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996;81:3299–3306
  54. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod. 2006;21:1400–1407

 D.G. has nothing to disclose. A.P.H. has nothing to disclose. C.H. has nothing to disclose. L.T.J. has nothing to disclose. J.F. has nothing to disclose. P.B. has nothing to disclose. A.F. has nothing to disclose. M.A. has nothing to disclose.

 Supported by Fonden for Lægevidenskabelig Forskning ved Fyns Amt, Jacob Madsen and Olga Madsen Foundation, Institute of Clinical Research, Odense University Hospital, A. P. Møller Foundation, Hans and Nora Buchard Foundation, K. A. Rohde Foundation, Aase and Ejnar Danielsen Foundation, Eva and Carl Adolf Holm Foundation, Dagmar Marshall Foundation, Danish Medical Association, A. J. Andersen Foundation, Novo Nordisk Foundation, Overlægerådet Odense University Hospital, Danish Diabetes Association, and Danish Medical Research Council.

PII: S0015-0282(08)00009-5

doi: 10.1016/j.fertnstert.2007.12.082

Fertility and Sterility
Volume 91, Issue 3 , Pages 842-850 , March 2009

Article Tools

* Image Usage & Resolution